Skip to main content

Grafa News and Videos — Page 1078

Grafa Headlines

Latest

Grafa

Alterity Therapeutics wins FDA alignment for pivotal Phase 3 neurodegenerative trial

Alterity Therapeutics (NASDAQ:ATHE) has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing critical regulatory alignment on the design of its upcoming pivotal Phase 3 clinical program for lead candidate ATH434.

Read more: Alterity Therapeutics wins FDA alignment for pivotal Phase 3 neurodegenerative trial
Grafa
Retail

J.M. Smucker Q4 earnings surge 20% as firm outlines 2027 outlook

The J.M. Smucker Company (NYSE:SJM) reported a 20% increase in fourth-quarter adjusted earnings per share, driven by favorable pricing actions and portfolio management, while issuing a forward-looking forecast that projects a modest revenue contraction for the upcoming fiscal year.

Read more: J.M. Smucker Q4 earnings surge 20% as firm outlines 2027 outlook
Grafa
Retail

Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance

Designer Brands (NYSE:DBI) reported a slight expansion in its first-quarter top-line revenue, driven by strong growth within its wholesale division that helped offset softening demand across its core brick-and-mortar storefront network.

Read more: Designer Brands Q1 sales edge higher on brand portfolio growth, reaffirms guidance

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift